News
Enara Bio to Unveil First‑in‑Class DARKFOX‑Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy
ENA101 was engineered using Enara’s proprietary EnTiCE® T cell engager platform, enabling potent redirection of T cells to destroy cancer cells while maintaining exquisite specificity and robust manufacturability. In multiple preclinical studies
Enara Bio enters 2026 with Dark Antigen licensing to Boehringer Ingelheim, appointment of Chief Medical Officer and plans to advance DARKFOX T-cell engager into First-in-Human studies
Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T-cell engagers for solid tumors, today announced that Boehringer Ingelheim has exercised its option to license multiple additional Dark Antigen targets discovered and validated through the collaboration with Enara
All News
Browse our full news archives
Upcoming & Recent Events
Discover the events that the Enara Bio team are attending